Leukemia inhibitory factor (LIF) receptor amplifies pathogenic activation of fibroblasts in lung fibrosis

Hung N Nguyen,Yunju Jeong,Yunhye Kim,Yaunghyun H Kim,Humra Athar,Peter J Castaldi,Craig P Hersh,Robert F Padera,Lynette M Sholl,Marina Vivero,Nirmal S Sharma,Jeong Yun,Louis T Merriam,Ke Yuan,Edy Yong Kim,Michael B Brenner

DOI: https://doi.org/10.1101/2024.05.21.595153

2024-05-23

Abstract:Fibrosis drives end-organ damage in many diseases. However, clinical trials targeting individual upstream activators of fibroblasts, such as TGFbeta, have largely failed. Here, we target the leukemia inhibitory factor receptor (LIFR) as a "master amplifier" of multiple upstream activators of lung fibroblasts. In idiopathic pulmonary fibrosis (IPF), the most common fibrotic lung disease, we found that lung myofibroblasts had high LIF expression. Further, TGFbeta1, one of the key drivers of fibrosis, upregulated LIF expression in IPF fibroblasts. In vitro anti-LIFR antibody blocking on human IPF lung fibroblasts reduced induction of profibrotic genes downstream of TGFbeta1, IL-4 and IL-13. Further, siRNA silencing of LIFR in IPF precision cut lung slices reduced expression of fibrotic proteins. Together, we find that LIFR drives an autocrine positive feedback loop that amplifies and sustains pathogenic activation of IPF fibroblasts downstream of multiple external stimuli, implicating LIFR as a therapeutic target in fibrosis.

Cell Biology

What problem does this paper attempt to address?

This paper primarily discusses the role of leukemia inhibitory factor receptor (LIFR) in pulmonary fibrosis. The study found that LIFR is highly expressed in lung fibroblasts, which are key cells involved in the fibrosis process, in idiopathic pulmonary fibrosis (IPF), the most common form of pulmonary fibrosis. TGF-β1, a key driver of fibrosis, upregulates the expression of LIF in IPF fibroblasts. Through blocking LIFR with antibodies or gene silencing experiments, researchers demonstrated that LIFR can amplify the effects of fibrotic factors such as TGF-β1, IL-4, and IL-13, thereby maintaining and enhancing the pathological activation of fibroblasts.

The paper suggests that the autocrine positive feedback loop mediated by LIFR amplifies the fibrotic gene program of IPF fibroblasts under various external stimuli, making LIFR a potential therapeutic target. Blocking LIFR may be more effective in combating fibrotic diseases compared to strategies targeting a single upstream activating factor, as it can integrate multiple fibrotic stimuli. The results of the study indicate that blocking the LIFR signaling pathway reduces the expression of fibrotic proteins in IPF lung tissue in vitro, providing a new strategy for the treatment of fibrotic diseases.